Hepatitis Delta in Focus: Episode 1 of Answering the Questions on Screening, Diagnosis, and Treatment

In this episode, Maria Buti, MD, and Richard H. Davis, PA-C, address key considerations when screening, diagnosing, and treating patients with hepatitis delta virus (HDV), such as:

• Barriers to screening 
• HDV screening based on patient risk factors 
• Universal screening for all patients with positive hepatitis B surface antigen (HBsAg)
• Reflex testing 
• Availability of commercial testing
• Monitoring suggestions in HBsAg positive and HDV antibody positive patients with negative HDV RNA
• Limitations to evaluating advanced fibrosis in patients with HDV
• Data on novel HDV therapies (eg, bulevirtide and lonafarnib)
• Extending HDV therapy (eg, peginterferon) based on treatment response
• Stopping rules (eg, HDV RNA negativity, HBsAg loss) for discontinuing HDV therapy

Faculty:

Maria Buti, MD
Professor of Medicine
Hospital Universitario Vall d’Hebron
Barcelona, Spain

Richard H. Davis, PA-C
Senior PA
Gastroenterology
University of Florida
UF Health
Gainesville, Florida

Link to full program: 
http://bit.ly/3yp1Lxf

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.